Nuevocor has successfully closed a US$45 million Series B funding round, co-led by Kurma Partners and Angelini Ventures, to advance its novel mechanobiology-centered therapy for LMNA-related dilated cardiomyopathy.

Target Information

Nuevocor is a biotechnology company headquartered in Singapore, focused on developing innovative therapies to address cardiomyopathies, particularly those arising from mechanobiological anomalies. Recently, the company has successfully completed a US$45 million Series B financing round, aimed at advancing its lead candidate, NVC-001, through clinical trials. This funding will specifically support a Phase 1/2 clinical trial for patients suffering from LMNA-related dilated cardiomyopathy (LMNA DCM), a genetic condition that weakens and enlarges the heart muscle.

Industry Overview

The market for cardiomyopathy treatment is experiencing significant growth, driven by the increasing prevalence of genetic heart diseases. LMNA DCM is estimated to affect over 100,000 patients across the U.S. and Europe, marking a substantial unmet medical need. The condition, caused by mutations in the LMNA gene, leads to severe complications, including end-stage heart failure.

The evolving landscape of cardiomyopathies highlights the urgency for novel treatment options. Companies like Nuevocor are emerging with innova